期刊文献+

Monolithic LC method applied to fesoterodine fumarate low dose extended-release tablets:Dissolution and release kinetics 被引量:2

下载PDF
导出
摘要 A dissolution test for fesoterodine low dose extended-release tablets using liquid chromatographic(LC) method equipped with a C18 monolithic column was developed and validated. LC system was operated isocratically at controlled temperature(40 1C) using a mobile phase of acetonitrile:methanol:0.03 M ammonium acetate(p H 3.8)(30:15:55, v/v/v), run at a flow rate of 1.5 m L/min and detected at 208 nm. The best dissolution conditions for this formulation were achieved using a USP apparatus 2(paddle) at 100 rpm and 900 m L of phosphate buffer at p H 6.8 as the dissolution medium.Validation parameters such as the specificity, linearity, accuracy, precision, and robustness were evaluated according to international guidelines, giving results within the acceptable range. The kinetic parameters of drug release were also investigated using model-dependent methods and the dissolution profiles were best described by the Higuchi model. The validated dissolution test can be applied for quality control of this formulation. A dissolution test for fesoterodine low dose extended-release tablets using liquid chromatographic(LC) method equipped with a C18 monolithic column was developed and validated. LC system was operated isocratically at controlled temperature(40 1C) using a mobile phase of acetonitrile:methanol:0.03 M ammonium acetate(p H 3.8)(30:15:55, v/v/v), run at a flow rate of 1.5 m L/min and detected at 208 nm. The best dissolution conditions for this formulation were achieved using a USP apparatus 2(paddle) at 100 rpm and 900 m L of phosphate buffer at p H 6.8 as the dissolution medium.Validation parameters such as the specificity, linearity, accuracy, precision, and robustness were evaluated according to international guidelines, giving results within the acceptable range. The kinetic parameters of drug release were also investigated using model-dependent methods and the dissolution profiles were best described by the Higuchi model. The validated dissolution test can be applied for quality control of this formulation.
出处 《Journal of Pharmaceutical Analysis》 CAS 2015年第2期137-141,共5页 药物分析学报(英文版)
基金 CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nível Superior) FAPERJ(Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro)for the financial support
  • 相关文献

参考文献19

  • 1P. Costa, J.M.S. Lobo, Modeling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133.
  • 2S. Dash, P.N. Murthy, L. Nath, et al., Kinetic modeling on drug release from controlled drug delivery systems, Acta Pol. Pharm. Drug Res. 67 (2010) 217-223.
  • 3Z. Gao, Mathematical modeling of variables involved in dissolution testing, J. Pharm. Sci. 100 (2011) 4934-4942.
  • 4B. Malhotra, Z. Guan, N. Wood, et al., Pharmacokinetic profile of fesoterodine, Int. J. Clin. Pharmacol. Ther. 46 (2008) 556-563.
  • 5CR. Chapple, V. Khullar, Z. Gabriel, et al., The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis, Eur. Urol. 54 (2008) 543-562.
  • 6J.M. Parekha, M. Sanyalb, M. Yadavc, et al., Investigation of ex vivo stability of fesoterodine in human plasma and its simultaneous determination together with its active metabolite 5-HMT by LCESI-MSIMS: application to a bioequivalence study, J. Chromatogr. B 913-914 (2013) I-II.
  • 7M.e. Michel, Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome, Expert. Opin. Pharmacother. 9 (2008) 1787-1796.
  • 8Food and Drug Administration, Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of in vitrolin vivo Correlations, Rockville, 1997, pp. 1-27.
  • 9S. Sakore, B. Chakraborty, In vitro-in vivo correlation (IVIVC): a strategic tool in drug development, J. Bioequiv. Availab. S3 (2011) SI-SI2.
  • 10J.A. Yanez, e.M. Remsberg, CL. Sayre, et a1., Flip-flop pharmacokinetics - delivering a reversal of disposition: challenges and opportunities during drug development, Ther. Deliv. 2 (2011) 64H72.

同被引文献5

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部